Clinical Trial

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Protocol Amendment History 31 amendments
This ClinicalTrials.gov record has been amended 31 times since 2023-07-31; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2023-09-07
Trial Details
NCT Number NCT05981703
Lead Sponsor BeOne Medicines
Conditions Advanced Solid Tumor, Solid Tumor
Enrollment 217 participants
Start Date 2023-09-21
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03